IBRI science frontiers logo

IBRI Science Frontiers
3rd Annual Seminar Series

Learn More

Optimizing Precision Regulatory Cell Therapy to Control Anti-drug Antibodies

Optimizing Precision Regulatory Cell Therapy to Control Anti-drug Antibodies

Wednesday, August 24, 2022
9:00 AM - 10:00 AM

Presenters: Moanaro Biswas, MSC, PhD

Organization: Wells Center for Pediatric Research at Indiana University, Indianapolis, Indiana

Moanaro Biswas, MSC, PhD, is an assistant research professor in the Gene and Cell Therapy Program at the Herman B. Wells Center for Pediatric Research at Indiana University School of Medicine, currently transitioning to a tenure track position. She was appointed to this position in May 2018.

She received her master’s degree and doctorate in biotechnology from India. She was previously appointed at the University of Florida as a postdoctoral research associate in the department of pediatrics. While at the University of Florida, she received the Henry A. Kokomoor Award for Excellence in Pediatric Research in 2017. 

As an early career investigator, Biswas has received multiple career development awards from the Bayer Hemophilia Awards Program, the National Hemophilia Foundation, and most recently, the American Society for Gene and Cell Therapy. She has received funding from industry, the US Department of Defense, and the National Institutes of Health, as well as from the Indiana CTSI (Clinical and Translational Sciences Institute) to pursue her research.

Biswas is interested in studying cell and drug-based therapies to control anti-drug antibody development. She uses therapeutic protein replacement therapy for the blood clotting disorder hemophilia as a model. Her research focus is on engineering regulatory T cells for antigen specificity, which has the potential to accomplish potent suppression at minimal doses. She is interested in improving engineered receptor design and in promoting engineered regulatory T cell stability and in vivo persistence. Her strategies to develop a superior cellular product for tolerance can be broadly applied to other therapeutic proteins, autoimmune disorders such as type I diabetes, or graft versus host disease.

Register now